2$...at 2$ it would be a pitty !
exemple of a successfull Phase 3 : Vertex Pharma
https://www.vrtx.com/
34$ US /share with 202 million shares, R&D 550 million in 2009, 110 million revenue in 2009 from an HIV drug marketed by Glaxo, + 1 new drug with 4 billion market (hepatis C - efficacy 75% May 25, to be marketed later...) + some more in the pipeline